ApoB vs LDL: When Normal Cholesterol Hides Artery Calcium

Jeff's Daily Pick. Your LDL can look normal while your arteries collect calcium. In a 25 year US study, a high ApoB with normal LDL meant 55% higher odds of coronary calcium.

In the United States, the standard cholesterol panel reports LDL cholesterol, the amount of cholesterol carried by LDL particles. ApoB counts the particles themselves, one ApoB protein per particle. Most of the time the two agree. A review published on September 30, 2026 in Frontiers in Cardiovascular Medicine summarized what happens when they do not, citing odds ratios of about 1.55 to 2.28 for coronary artery calcium. Those numbers trace back to one well known study.

Where 1.55 and 2.28 come from

The CARDIA study, published in the Journal of the American College of Cardiology in 2016, measured ApoB in 2,794 young adults aged 18 to 30 and scanned their coronary arteries 25 years later. Compared with the lowest third of ApoB, the middle third had an odds ratio of 1.53 for any coronary calcium, and the highest third 2.28, after adjusting for traditional risk factors. People whose ApoB was high while their LDL was low, a discordant pattern, had an odds ratio of about 1.55. The reverse pattern, high LDL with low ApoB, did not carry the same excess.

The 2026 twist

A study in the Journal of Clinical Lipidology this year followed 15,738 adults with a median age of 37 who had repeated calcium scans over a median of 6 years. Calcium progressed in 19.5%. Among people with obesity but no metabolic syndrome components, those with discordantly high ApoB had an odds ratio of 1.74 for progression (95% CI 1.13 to 2.66), close to people who were metabolically unhealthy. Those with discordantly low ApoB showed no excess (1.03). High discordance also raised risk in lean, metabolically healthy people (1.73).

Who the test helps

A JACC: Advances paper this autumn argued for selective rather than universal ApoB testing. Discordance is common with triglycerides of 150 mg/dL or more, diabetes and metabolic syndrome. In most untreated people without significant cardiometabolic risk, the authors wrote, LDL and ApoB rarely diverge and the extra test does not change management. The useful question is therefore narrow: in someone with high triglycerides or insulin resistance whose LDL looks fine, ApoB can reveal a particle burden the standard panel misses. Our earlier piece on an oral PCSK9 pill covers how ApoB is used as a treatment target.